Afatinib for lung cancer: Let there be light?

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 133-134

  Garassino, Marina C ^a   Torri, Valter ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; EGFR GENE; GENE MUTATION; HUMAN; LETTER; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK REDUCTION; STOMATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84892974623     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70002-6     Document Type: Letter

References (10)

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF Management of non-small lung cancer: recent developments. Lancet 2013, 382:709-719.
2. Rosell R, Bivona TG, Karachaliou N Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382:720-731.
3. Tomida S, Yatabe Y, Yanagisawa K, et al. Throwing new light on lung cancer pathogenesis: updates on three recent topics. Cancer Sci 2005, 96:63-68.
4. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013, 105:595-605.
5. Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, published online Jan 15. http://dx.doi.org/10.1016/S1470-2045(13)70604-1.
6. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
7. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
8. Yang JC, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer. 15th IASLC World Conference on Lung Cancer; Sydney, Australia; Oct 27-31, 2013. abstr O03.05.
9. Pilotto S, Di Maio M, Peretti U Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: sensitivity and meta-regression analysis of randomized trials. Crit Rev Oncol Hematol 2013, 8428:252-257.
10. Haspinger E, Agustoni F, Gelsomino F, et al. Indirect comparisons of harm/benefit profile of EGFR tyrosine kinase inhibitors as first line treatment in EGFR mutated NSCLC patients: a systematic review and meta-analysis. 15th IASLC World Conference on Lung Cancer; Sydney, Australia; Oct 27-31, 2013. abstr P2.11-034.